BRIDGEWATER, NJ--(Marketwire - October 15, 2007) - Alpharma Pharmaceuticals LLC, a subsidiary of Alpharma Inc. (NYSE: ALO), a leading global specialty pharmaceutical company, presented results from a Phase 2 study that showed ALO-01, an extended-release morphine sulfate plus sequestered naltrexone, provided similar effectiveness to KADIAN® (morphine sulfate extended-release) Capsules in osteoarthritis patients with moderate-to-severe chronic pain. The data were presented at the annual meeting of the American Society of Anesthesiologists in San Francisco, Calif., on October 15, 2007.
